<?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName JATS-journalpublishing1.dtd?>
<?SourceDTD.Version 1.1?>
<?ConverterInfo.XSLTName jats2jats3.xsl?>
<?ConverterInfo.Version 1?>
<?properties open_access?>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Database (Oxford)</journal-id>
    <journal-id journal-id-type="iso-abbrev">Database (Oxford)</journal-id>
    <journal-id journal-id-type="publisher-id">databa</journal-id>
    <journal-title-group>
      <journal-title>Database: The Journal of Biological Databases and Curation</journal-title>
    </journal-title-group>
    <issn pub-type="epub">1758-0463</issn>
    <publisher>
      <publisher-name>Oxford University Press</publisher-name>
      <publisher-loc>UK</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">8234134</article-id>
    <article-id pub-id-type="doi">10.1093/database/baab037</article-id>
    <article-id pub-id-type="publisher-id">baab037</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Original Article</subject>
      </subj-group>
      <subj-group subj-group-type="category-taxonomy-collection">
        <subject>AcademicSubjects/SCI00960</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>KMDATA: a curated database of reconstructed individual patient-level data from 153 oncology clinical trials</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6436-6691</contrib-id>
        <name>
          <surname>Fell</surname>
          <given-names>Geoffrey</given-names>
        </name>
        <xref rid="FN001" ref-type="author-notes"/>
        <aff><institution content-type="department">Department of Data Science, Dana-Farber Cancer Institute</institution>, 450 Brookline Ave, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Redd</surname>
          <given-names>Robert A</given-names>
        </name>
        <xref rid="FN001" ref-type="author-notes"/>
        <aff><institution content-type="department">Department of Data Science, Dana-Farber Cancer Institute</institution>, 450 Brookline Ave, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Vanderbeek</surname>
          <given-names>Alyssa M</given-names>
        </name>
        <aff><institution content-type="department">Clinical Trials and Statistics Unit, Institute of Cancer Research</institution>, 123 Old Brompton Road, Sutton, London SW73RP, <country country="GB">UK</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9443-1797</contrib-id>
        <name>
          <surname>Rahman</surname>
          <given-names>Rifaquat</given-names>
        </name>
        <aff><institution content-type="department">Department of Radiation Oncology, Harvard Medical School</institution>, 25 Shattuck St, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution content-type="department">Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center</institution>, 450 Brookline Ave, Boston, MA 02215, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Louv</surname>
          <given-names>Bill</given-names>
        </name>
        <aff><institution>Project Data Sphere</institution>, 1204 Village Market Place, Suite 288, Morrisville, NC 27560, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>McDunn</surname>
          <given-names>Jon</given-names>
        </name>
        <aff><institution>Project Data Sphere</institution>, 1204 Village Market Place, Suite 288, Morrisville, NC 27560, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Arfè</surname>
          <given-names>Andrea</given-names>
        </name>
        <aff><institution content-type="department">Department of Data Science, Dana-Farber Cancer Institute</institution>, 450 Brookline Ave, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution content-type="department">Department of Radiation Oncology, Harvard Medical School</institution>, 25 Shattuck St, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Alexander</surname>
          <given-names>Brian M</given-names>
        </name>
        <aff><institution content-type="department">Department of Radiation Oncology, Harvard Medical School</institution>, 25 Shattuck St, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution content-type="department">Department of Radiation Oncology, Dana-Farber/Brigham and Women’s Cancer Center</institution>, 450 Brookline Ave, Boston, MA 02215, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2229-9560</contrib-id>
        <name>
          <surname>Ventz</surname>
          <given-names>Steffen</given-names>
        </name>
        <xref rid="FN002" ref-type="author-notes"/>
        <!--steffen@ds.dfci.harvard.edu-->
        <xref rid="COR0001" ref-type="corresp"/>
        <aff><institution content-type="department">Department of Data Science, Dana-Farber Cancer Institute</institution>, 450 Brookline Ave, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution content-type="department">Department of Biostatistics, Harvard T.H. Chan School of Public Health</institution>, 677 Huntington Ave, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Trippa</surname>
          <given-names>Lorenzo</given-names>
        </name>
        <xref rid="FN002" ref-type="author-notes"/>
        <!--ltrippa@ds.dfci.harvard.edu-->
        <xref rid="COR0002" ref-type="corresp"/>
        <aff><institution content-type="department">Department of Data Science, Dana-Farber Cancer Institute</institution>, 450 Brookline Ave, Boston, MA 02115, <country country="US">USA</country></aff>
        <aff><institution content-type="department">Department of Biostatistics, Harvard T.H. Chan School of Public Health</institution>, 677 Huntington Ave, Boston, MA 02115, <country country="US">USA</country></aff>
      </contrib>
    </contrib-group>
    <author-notes>
      <corresp id="COR0001">*Corresponding author: Tel: +617-632-5296; Fax: +617-394-2667; Email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="steffen@ds.dfci.harvard.edu">steffen@ds.dfci.harvard.edu</email></corresp>
      <corresp id="COR0002">Correspondence may also be addressed to Lorenzo Trippa. Tel: +617-8757-578; Fax: +617-394-2667; Email: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ltrippa@ds.dfci.harvard.edu">ltrippa@ds.dfci.harvard.edu</email></corresp>
      <fn id="FN001">
        <label>
          <sup>†</sup>
        </label>
        <p>Co-first author.</p>
      </fn>
      <fn id="FN002">
        <label>
          <sup>‡</sup>
        </label>
        <p>Co-senior author.</p>
      </fn>
    </author-notes>
    <pub-date pub-type="collection">
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="epub" iso-8601-date="2021-06-26">
      <day>26</day>
      <month>6</month>
      <year>2021</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>26</day>
      <month>6</month>
      <year>2021</year>
    </pub-date>
    <volume>2021</volume>
    <elocation-id>baab037</elocation-id>
    <history>
      <date date-type="received">
        <day>09</day>
        <month>3</month>
        <year>2021</year>
      </date>
      <date date-type="rev-recd">
        <day>24</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>27</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="editorial-decision">
        <day>25</day>
        <month>5</month>
        <year>2021</year>
      </date>
      <date date-type="corrected-typeset">
        <day>23</day>
        <month>6</month>
        <year>2021</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2021. Published by Oxford University Press.</copyright-statement>
      <copyright-year>2020</copyright-year>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
      </license>
    </permissions>
    <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab037.pdf"/>
    <abstract>
      <title>Abstract</title>
      <p>We created a database of reconstructed patient-level data from published clinical trials that includes multiple time-to-event outcomes such as overall survival and progression-free survival. Outcomes were extracted from Kaplan–Meier (KM) curves reported in 153 oncology Phase III clinical trial publications identified through a PubMed search of clinical trials in breast, lung, prostate and colorectal cancer, published between 2014 and 2016. For each trial that met our search criteria, we curated study-level information and digitized all reported KM curves with the software <italic toggle="yes">Digitizelt</italic>. We then used the digitized KM survival curves to estimate (possibly censored) patient-level time-to-event outcomes. Collections of time-to-event datasets from completed trials can be used to support the choice of appropriate trial designs for future clinical studies. Patient-level data allow investigators to tailor clinical trial designs to diseases and classes of treatments. Patient-level data also allow investigators to estimate the operating characteristics (e.g. power and type I error rate) of candidate statistical designs and methods.</p>
      <p><bold>Database URL</bold>: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://10.6084/m9.figshare.14642247.v1" ext-link-type="uri">https://10.6084/m9.figshare.14642247.v1</ext-link></p>
    </abstract>
    <funding-group>
      <award-group award-type="grant">
        <funding-source>
          <institution-wrap>
            <institution>National Institutes of Health</institution>
            <institution-id institution-id-type="DOI">10.13039/100000002</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>1R01LM013352-01A1</award-id>
      </award-group>
    </funding-group>
    <counts>
      <page-count count="6"/>
    </counts>
  </article-meta>
</front>
<body>
  <sec id="s3">
    <title>Introduction</title>
    <p>The magnitude and form of treatment effects in cancer clinical trials (e.g. early, delayed or persistent improvements of survival probabilities (<xref rid="R1" ref-type="bibr">1</xref>) relative to the standard of care) can vary substantially across malignancies, patient populations and classes of anti-cancer therapeutics (<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R2" ref-type="bibr">2</xref>). This makes the design and analysis of cancer clinical trials with time-to-event primary outcomes challenging. Collections of survival data from completed clinical trials and real-world datasets can support the choice of study designs and statistical procedures for future clinical studies (<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R4" ref-type="bibr">4</xref>). In particular, datasets from completed trials can enable the estimation and comparison of operating characteristics (e.g. power, type I error rate and the risk of exposing patients to inferior treatments) of various study designs and statistical methods (e.g. proportional hazards and accelerated failure-time models). Importantly, study designs and statistical methods can be evaluated with retrospective analyses that focus on a specific disease (<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R6" ref-type="bibr">6</xref>) or on a class of treatment (<xref rid="R7" ref-type="bibr">7</xref>).</p>
    <p>Individual patient-level data (IPLD) from completed clinical trials can support key decisions in future studies. These data can inform the selection of suitable metrics to quantify treatment effects (e.g. difference in median survival, or the restricted mean survival). For example, the hazard ratio (HR) can be difficult to interpret in settings where, based on previous experience, one expects delayed treatment effects on overall survival (OS) (<xref rid="R8" ref-type="bibr">8</xref>). IPLD can also help predict the operating characteristics of candidate data-analysis procedures. Rahman <italic toggle="yes">et al.</italic> (<xref rid="R1" ref-type="bibr">1</xref>) and Uno <italic toggle="yes">et al.</italic> (<xref rid="R9" ref-type="bibr">9</xref>) showed the utility of leveraging context-specific data from completed clinical trials to select suitable data-analysis techniques. Retrospective analyses of survival data from completed trials can complement or replace the use of arbitrarily selected simulation scenarios to compare designs and methodologies (<xref rid="R10" ref-type="bibr">10</xref>). Finally, IPLD can be used for planning interim analyses and decisions during the trial. For example, Ventz <italic toggle="yes">et al.</italic> (<xref rid="R11" ref-type="bibr">11</xref>). discussed non-inferiority designs based on a collection of head and neck cancer datasets and provided recommendations on interim monitoring procedures for future head and neck cancer trials.</p>
    <p>Although several important initiatives have facilitated access to IPLD from completed clinical trials (<xref rid="R12" ref-type="bibr">12–14</xref>), access to survival data from clinical studies remains limited, and typically it does not include recent trials. Additionally, in our experience, data repositories require research proposals and time-consuming procedures to obtain access to clinical trial datasets.</p>
    <p>We created a database of reconstructed IPLD that includes individual time-to-event outcomes, such as OS and progression-free survival (PFS). These outcomes were extracted from Kaplan–Meier (KM) survival curves (<xref rid="R15" ref-type="bibr">15</xref>) reported in 153 Phase III oncology studies in breast, lung, prostate and colorectal cancer, published between 2014 and 2016 in eight major oncology journals: <italic toggle="yes">Annals of Oncology</italic>, <italic toggle="yes">Lancet, Lancet Oncology</italic>, <italic toggle="yes">Journal of the American Medical Association (JAMA)</italic>, <italic toggle="yes">JAMA Oncology</italic>, <italic toggle="yes">Journal of Clinical Oncology</italic>, <italic toggle="yes">Journal of the National Cancer Institute</italic> and <italic toggle="yes">New England Journal of Medicine.</italic> We discuss small discrepancies between our estimates of the IPLD outcomes and those in the actual datasets. Importantly, our reconstructed KM and IPDL are directly available and downloadable by interested users. Moreover, our database can be used for comparisons of statistical designs and methodologies.</p>
  </sec>
  <sec id="s4">
    <title>Database</title>
    <sec id="s4-s1">
      <title>Inclusion criteria</title>
      <p>A PubMed search was performed on 4 December 2017. MeSH search terms included ‘<italic toggle="yes">breast cancer</italic>’, ‘<italic toggle="yes">lung cancer</italic>’, ‘<italic toggle="yes">prostate cancer</italic>’ or ‘<italic toggle="yes">colorectal cancer</italic>’, and results were limited to Phase III clinical studies, published between 1 January 2014 and 31 December 2016 in eight major clinical journals: <italic toggle="yes">Annals of Oncology</italic>, <italic toggle="yes">Lancet, Lancet Oncology</italic>, <italic toggle="yes">Journal of the American Medical Association (JAMA)</italic>, <italic toggle="yes">JAMA Oncology, Journal of Clinical Oncology</italic>, <italic toggle="yes">Journal of the National Cancer Institute</italic> and <italic toggle="yes">New England Journal of Medicine.</italic> We further restricted results to clinical studies with tumor-directed interventions that reported at least one time-to-event outcome with KM curves. Time-to-event outcomes included OS, PFS, disease-free survival and relapse-free survival. <xref rid="F1" ref-type="fig">Figure 1</xref> summarizes our search and inclusion/exclusion criteria.</p>
      <fig position="float" id="F1" fig-type="figure">
        <label>Figure 1.</label>
        <caption>
          <p>PRISMA selection of clinical trials included in KMDATA. The original PubMed search resulted in 836 total publications. Results were excluded based on prespecified criteria including cancer type and study endpoints. A total of 153 publications from clinical trials were included in the database.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab037f1" position="float"/>
      </fig>
      <p>The PubMed search identified 153 published clinical trials. The identified manuscripts included 304 KM graphs that compared the distributions of time-to-event outcomes in the experimental and control arms. We call these graphs ‘KM pairs’. For clinical trials with multiple experimental arms and a control group, we defined ‘KM pairs’ for each experimental treatment. The average sample size per treatment arm was 432 (SD = 448, range = 31–2661). For each KM pair, we extracted and curated study-level information on the cancer type, publication date, journal, trial registration ID, PubMed ID, type of intervention, type of experimental therapy, trial population, trial design, randomization ratio, sample size, primary endpoint(s), reported HR and <italic toggle="yes">P</italic>-values for the primary endpoints.</p>
      <sec id="s4-s1-s1">
        <title>Reconstructed IPLD</title>
        <p>For each of the 153 studies that met our search criteria, all KM survival curves were extracted from the publication as a raster image. Next, we obtained the coordinates <inline-formula id="ILM0001"><tex-math id="M1">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\left\{ {\left[ {{t_i}, \hat S\left( {{t_i}} \right)} \right]; i = 1, \ldots , d} \right\}$\end{document}</tex-math></inline-formula> of the KM curves with the software <italic toggle="yes">Digitizelt</italic> (<xref rid="R16" ref-type="bibr">16</xref>). Here, <inline-formula id="ILM0002"><tex-math id="M2">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\hat S\left( {{t_i}} \right) $\end{document}</tex-math></inline-formula>indicates the KM estimate of the survival function at event times <inline-formula id="ILM0003"><tex-math id="M3">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${t_i}$\end{document}</tex-math></inline-formula>, <inline-formula id="ILM0004"><tex-math id="M4">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$i = 1, \ldots , d$\end{document}</tex-math></inline-formula>. Patients-at-risk tables are often included at the bottom of KM graphs. We extracted these patients-at-risk tables <inline-formula id="ILM0005"><tex-math id="M5">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\left\{ {\left( {{{\tilde t}_i}, {r_i}} \right); i = 1, \ldots , D} \right\}$\end{document}</tex-math></inline-formula> from the publications. In OS analyses, <inline-formula id="ILM0006"><tex-math id="M6">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${r_i}$\end{document}</tex-math></inline-formula> indicates the number of patients with survival larger than <inline-formula id="ILM0007"><tex-math id="M7">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\tilde t_i}$\end{document}</tex-math></inline-formula>; more generally, in time-to-event analyses, <inline-formula id="ILM0008"><tex-math id="M8">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${r_i}$\end{document}</tex-math></inline-formula> is the number of patients at risk at time <inline-formula id="ILM0009"><tex-math id="M9">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${\tilde t_i}$\end{document}</tex-math></inline-formula>.</p>
        <p>Next, we used the KM survival curve <inline-formula id="ILM0010"><tex-math id="M10">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\{ ({t_i}, \hat S\left( {{t_i}} \right); i = 1, \ldots , d\} $\end{document}</tex-math></inline-formula>, together with the patients-at-risk table <inline-formula id="ILM0011"><tex-math id="M11">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\left\{ { \left( {{{\tilde t}_i}, {r_i}} \right); i = 1, \ldots , D} \right\}$\end{document}</tex-math></inline-formula> if it was available, to estimate patient-level time-to-event outcomes with censoring <inline-formula id="ILM0012"><tex-math id="M12">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\left\{ { \left( {{T_j}, {C_j}} \right); j = 1, \ldots , n} \right\}$\end{document}</tex-math></inline-formula>. Following the standard notation of time-to-event analyses, <inline-formula id="ILM0013"><tex-math id="M13">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$j = 1, \ldots , n $\end{document}</tex-math></inline-formula>indexes patients and <inline-formula id="ILM0014"><tex-math id="M14">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${C_j} \in \left\{ {0,1} \right\}$\end{document}</tex-math></inline-formula> indicates if the time variable <inline-formula id="ILM0015"><tex-math id="M15">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${T_j}$\end{document}</tex-math></inline-formula> corresponds to an observed event (<inline-formula id="ILM0016"><tex-math id="M16">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${C_j} = 1, $\end{document}</tex-math></inline-formula> e.g. the patient’s death in OS analyses) or to a censored event (<inline-formula id="ILM0017"><tex-math id="M17">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${C_j} = 0, $\end{document}</tex-math></inline-formula> e.g. patient <inline-formula id="ILM0018"><tex-math id="M18">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$j$\end{document}</tex-math></inline-formula> was alive at the end of a follow-up period of <inline-formula id="ILM0019"><tex-math id="M19">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${T_j}$\end{document}</tex-math></inline-formula> months in OS analyses). We estimated the individual variables <inline-formula id="ILM0020"><tex-math id="M20">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$\left( {{T_j}, {C_j}} \right)$\end{document}</tex-math></inline-formula> with the algorithm proposed by Guyot <italic toggle="yes">et al.</italic> (<xref rid="R17" ref-type="bibr">17</xref>).</p>
      </sec>
    </sec>
    <sec id="s4-s2">
      <title>Data structure</title>
      <p>The KMDATA database is available in two forms: an excel file (MASTER.DATA.xlsx), available from <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://10.6084/m9.figshare.14642247.v1" ext-link-type="uri">10.6084/m9.figshare.14642247.v1</ext-link>), or an R package (<italic toggle="yes">kmdata)</italic>, available on GitHub at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/raredd/kmdata" ext-link-type="uri">https://github.com/raredd/kmdata</ext-link> (<xref rid="R18" ref-type="bibr">18</xref>). Both formats include study-level metadata, demographic information and the reconstructed IPLD (<xref rid="F2" ref-type="fig">Figure 2</xref>). The R package also implements the Guyot algorithm (<xref rid="R17" ref-type="bibr">17</xref>) for users interested in reconstructing IPLD from KM images using the <italic toggle="yes">ipd</italic> function.</p>
      <fig position="float" id="F2" fig-type="figure">
        <label>Figure 2.</label>
        <caption>
          <p>KMDATA structure. Each publication (A) was digitized (B) and processed using the Guyot algorithm to obtain time-to-event reconstructed data (C). The digitalized figures are included in the <bold><italic toggle="yes">kmdata</italic></bold> package. (D) Example of the reconstructed figures.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab037f2" position="float"/>
      </fig>
      <sec id="s4-s2-s1">
        <title>Study-level metadata</title>
        <p>This table contains 23 variables for each KM pair (<xref rid="F2" ref-type="fig">Figure 2A</xref>). These variables include the <italic toggle="yes">PubMed-ID</italic> of the publication from which we extracted the KM pair, the reported sample size of the study, the cancer type, the type of intervention and the primary outcome. The variable <italic toggle="yes">ID</italic> links the KM pairs in the study-level metadata table and the reconstructed IPLD table (RIPLD).</p>
        <p>Multiple entries (rows) of the study-level metadata table may be dedicated to each clinical study. Indeed, clinical studies typically report KM curves for multiple endpoints (OS, PFS, etc.) and in various patient subpopulations. These entries have the same <italic toggle="yes">PubMed-ID</italic> and clinical-trial identifiers, while the variables <italic toggle="yes">Subgroups</italic> and <italic toggle="yes">Outcome</italic> indicate the subpopulation and the endpoint described by the KM pair. The variable <italic toggle="yes">Figure</italic> identifies the figure and panel of the article from which we extracted the KM pair, <italic toggle="yes">Units</italic> indicates the time scale (weeks, months or years from enrollment), <italic toggle="yes">Treatment-Arms</italic> indicates the control and experimental treatments and <italic toggle="yes">Intervention-Class</italic> classifies the experimental treatments (categories include chemotherapy, immunotherapy, targeted therapy and surgical intervention).</p>
      </sec>
      <sec id="s4-s2-s2">
        <title>Example</title>
        <p>The first entry in <xref rid="F2" ref-type="fig">Figure 2A</xref> corresponds to a KM pair from <xref rid="F2" ref-type="fig">Figure 2A</xref> (figure) of the lung cancer (cancer) study ATTENTION (clinical trial) published in Annals of Oncology (Journal). The reported sample size of ATTENTION was 460 (sample size) patients, and the KM pair describes the OS (<italic toggle="yes">Outcome</italic>) outcome in the Epidermal Growth Factor Receptor (EGFR)-wildtype (subgroups) subpopulation.</p>
      </sec>
      <sec id="s4-s2-s3">
        <title>Demographics</title>
        <p>This table contains 12 variables. It reports, for each clinical study (publication) and treatment arm (therapy), demographic information of the enrolled patients, such as the number of male and female patients (sex:males, sex:females) and the median age at enrollment (median age).</p>
      </sec>
      <sec id="s4-s2-s4">
        <title>Reconstructed IPLD</title>
        <p>The RIPLD table contains, for each of the 304 KM pairs, the reconstructed (possible censored) patient-level time-to-event outcomes. This table has five columns: ID, time, time unit, event and arm. The variable <italic toggle="yes">ID</italic> (first column in both study-level metadata and RIPLD tables) provides a unique identifier to link the KM pairs listed in the study-level metadata table to the reconstructed time-to-event outcomes in the RIPLD file. For example, all RIPLD rows with <italic toggle="yes">ID</italic> ATTENTION_2A correspond to the OS KM curves (the <italic toggle="yes">Outcome</italic> variable for the ATTENTION_2A column in the study-level metadata file) in <xref rid="F2" ref-type="fig">Figure 2A</xref> of Yoshioka <italic toggle="yes">et al.</italic>, 2015 (<xref rid="R19" ref-type="bibr">19</xref>) for the ATTENTION trial.</p>
        <p>The variables <italic toggle="yes">time</italic> and <italic toggle="yes">event</italic> in the RIPLD file provide the reconstructed event-times <inline-formula id="ILM0021"><tex-math id="M21">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${T_j}$\end{document}</tex-math></inline-formula> and censoring indicators<inline-formula id="ILM0022"><tex-math id="M22">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$ {C_j}.$\end{document}</tex-math></inline-formula> Also, the variable <italic toggle="yes">time unit</italic> (weeks, months or years from enrollment) indicates the unit of measure of <inline-formula id="ILM0023"><tex-math id="M23">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${T_j}$\end{document}</tex-math></inline-formula> and the variable <italic toggle="yes">arm</italic> assigns the reconstructed outcome (<inline-formula id="ILM0024"><tex-math id="M24">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${T_j}$\end{document}</tex-math></inline-formula>, <inline-formula id="ILM0025"><tex-math id="M25">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${C_j}$\end{document}</tex-math></inline-formula>) to the experimental or the control arm.</p>
      </sec>
      <sec id="s4-s2-s5">
        <title>Example</title>
        <p>The first entry in the <italic toggle="yes">RIPLD</italic> table in <xref rid="F2" ref-type="fig">Figure 2C</xref>, (i.e. <italic toggle="yes">ID:</italic> ATTENTION_2A, <italic toggle="yes">time</italic>: 0.295, <italic toggle="yes">time unit</italic>: months, <italic toggle="yes">event</italic>: 0, <italic toggle="yes">arm:</italic> placebo) is a reconstructed OS outcome from the publication of the <italic toggle="yes">lung cancer</italic> study <italic toggle="yes">ATTENTION</italic> (<xref rid="R19" ref-type="bibr">19</xref>). It refers to an EGFR-wildtype patient randomized to the <italic toggle="yes">placebo</italic> arm with censored OS-time <inline-formula id="ILM0026"><tex-math id="M26">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}$({C_j} = 0)$\end{document}</tex-math></inline-formula> after <inline-formula id="ILM0027"><tex-math id="M27">\documentclass[12pt]{minimal}
\usepackage{amsmath}
\usepackage{wasysym}
\usepackage{amsfonts}
\usepackage{amssymb}
\usepackage{amsbsy}
\usepackage{upgreek}
\usepackage{mathrsfs}
\setlength{\oddsidemargin}{-69pt}
\begin{document}
}{}${T_j} = 0.295$\end{document}</tex-math></inline-formula> months from randomization.</p>
      </sec>
    </sec>
    <sec id="s4-s3">
      <title>Validation analysis</title>
      <p>We computed several summary statistics from our <italic toggle="yes">RIPLD</italic> and compared them to those reported in the publications. We focused on four measures:</p>
      <list list-type="roman-lower">
        <list-item>
          <p>The estimated HR between the experimental and control treatments, using a univariate Cox proportional hazards model,</p>
        </list-item>
        <list-item>
          <p>The median event-time in each treatment arm,</p>
        </list-item>
        <list-item>
          <p>The number of events and</p>
        </list-item>
        <list-item>
          <p>The number of patients at risk, as reported in the patients-at-risk tables.</p>
        </list-item>
      </list>
      <p>For each of these summaries, the scatterplots in <xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S1</xref> show data summaries reported in the publications (<italic toggle="yes">x</italic>-axis) against the summaries computed with the RIPLD (<italic toggle="yes">y</italic>-axis). Points close to the diagonal line indicate matched and recovered data summaries, whereas points far from the diagonal line indicate datasets with RIPLD summaries that deviate from the published results.</p>
      <p>The table <italic toggle="yes">ts2</italic> included in KMDATA (in the Excel file MASTER.DATA.xlsx) indicates, for each of the four summary measures, the absolute (<italic toggle="yes">Abs.Diff</italic>) and relative (<italic toggle="yes">Rel.Diff</italic>) difference between published and reconstructed data summaries. These discrepancy measures can be used to filter KM pairs with limited agreement between reconstructed and published data summaries, according to user-specified criteria.</p>
    </sec>
    <sec id="s4-s4">
      <title>Validation analysis based on datasets from Project Data Sphere (PDS)</title>
      <p>We identified six trials (NCT00703326, NCT00785291, NCT00981058, NCT00988208, NCT00988208 and NCT01193244) in the KMDATA database that were available for download from PDS (<xref rid="R20" ref-type="bibr">20</xref>), a data repository of completed clinical trials. For all six datasets, IPLD were only available for the control arms of the study. We randomly selected three of them (NCT00703326, NCT00785291, NCT00981058) and compared the actual IPLD from PDS and our reconstructed IPLD. The comparison is based on KM graphs computed using (i) the actual IPLD from PDS or (ii) our reconstructed IPLD from the digitalized publications. For the ROSE study (NCT00703326), the version of the dataset from PDS and the version reported in Mackey <italic toggle="yes">et al.</italic> (<xref rid="R21" ref-type="bibr">21</xref>), as well as the corresponding follow-up periods, are different.</p>
      <p><xref rid="sup1" ref-type="supplementary-material">Supplementary Figure S2</xref> illustrates that the KM curves in black (actual IPLD data) and blue (reconstructed IPLD data) are almost identical for the CALGB40502 (<xref rid="R21" ref-type="bibr">21</xref>) (NCT00785291) and SQUIRE (<xref rid="R22" ref-type="bibr">22</xref>) (NCT00981058) studies. As expected, for the ROSE study (NCT00703326) we observe some discrepancies between the black and blue KM curves. These are due to different follow-up periods and versions of the dataset presented in Mackey <italic toggle="yes">et al.</italic> (<xref rid="R21" ref-type="bibr">21</xref>) (the digitalized manuscript) and in the PDS platform.</p>
    </sec>
    <sec id="s4-s5">
      <title>Usage notes</title>
      <p>The KMDATA database can be accessed for data analyses with R (<xref rid="R23" ref-type="bibr">23</xref>) (package <bold><italic toggle="yes">kmdata)</italic></bold>. We illustrate an example here. We consider OS in the lung cancer study ACT1 (PMID25794890). We illustrate how to compare the experimental and control arms with a log-rank test, estimate the HR between these two arms and graph the reconstructed data.</p>
      <p><italic toggle="yes">\(# install the kmdata package\)</italic><italic toggle="yes">\(# install.packages(\)\!\!\!\!‘\(devtools\)’\!\!\!\!)</italic>devtools::install_github(\!\!\!\!‘raredd/kmdata’\!\!\!\!,
\, build_vignettes=TRUE)
library(\!\!\!\!‘kmdata’\!\!\!\!)</p>
      <p>
KM.pairs= ls(\!\!\!\!‘package:kmdata’\!\!\!\!)length(KM.pairs) <italic toggle="yes">\(# number of KM pairs\)</italic>
## [1] 308</p>
      <p>
KM.pairs[1:5]    <italic toggle="yes">\(# first 5 objects of the\)</italic><italic toggle="yes">\, database</italic>
## [1] "ACT1_2A" "ACT1_3A" "ACT2_2A"\, "ACT2_2B" "ACT2_2C"
000
</p>
      <p>Next, we print the first entries of the OS RIPLD for <italic toggle="yes">ACT1(</italic><xref rid="F2" ref-type="fig">Figure 2A</xref><italic toggle="yes">in PMID25794890).</italic> Use help(ACT1_2A) and attributes(ACT1_2A) to obtain information about the reconstructed IPLD for <xref rid="F2" ref-type="fig">Figure 2A</xref> of ACT1, including trial-level information and quality scores for the reconstruction.</p>
      <p>head(ACT1_2A)    <italic toggle="yes">\(# look at first entries\)</italic>
##   time event      arm## 1 0.210   0 amrubicin## 2 0.336   1 amrubicin## 3 0.336   1 amrubicin
000
</p>
      <p>We then use the RIPLD and a log-rank test to compare the OS survival distributions of the experimental (amrubicin) and control (topotecan) arms.</p>
      <p>S = Surv(ACT1_2A$time, ACT1_2A$event) <italic toggle="yes">\(# create\)</italic><italic toggle="yes">\, \(\, survival object\)</italic>survdiff(S ~ ACT1_2A$arm)             <italic toggle="yes">\(# log\)-\(rank\)</italic><italic toggle="yes">\, \(\, test\)</italic>
## Call:## survdiff(formula = S \(\sim\) ACT1_2A$arm)####      N Observed Expected (O-E)^2/E (O-E)\(\widehat{\phantom{x}}\)2/V## ACT1_2A$arm=topotecan 213 175 161 1.306 1.94## ACT1_2A$arm=amrubicin 424 333 347 0.603 1.94#### Chisq= 1.9 on 1 degrees of freedom, p= 0.2
000
</p>
      <p>Last, we fit a Cox proportional hazards model to estimate the HR and use the function <bold>kmplot()</bold> to plot the reconstructed KM curves.</p>
      <p>summary(coxph(S \(\sim\) ACT1_2A$arm))$coefficients
##         coef exp(coef) se(coef) z Pr(&gt;|z|)## ACT1_2A$armamrubicin -0.1307436 0.87744280.09359198 -1.396953 0.1624278
kmplot(ACT1_2A)
000
</p>
      <sec id="s4-s5-s1">
        <title>Note</title>
        <p>After installing the <bold><italic toggle="yes">kmdata</italic></bold> package from github (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://github.com/raredd/kmdata" ext-link-type="uri">https://github.com/raredd/kmdata</ext-link>), a detailed explanation of the <bold><italic toggle="yes">ipd()</italic></bold> function, which reconstructs the IPLD, is available via <bold>help(topic = ‘ipd’)</bold>. The data-frame <bold><italic toggle="yes">kmdata_key</italic></bold> in <bold><italic toggle="yes">kmdata</italic></bold> contains the <italic toggle="yes">Study-level metadata</italic> table, use <bold>head(kmdata_key)</bold> to print the first six entries of the table. The R code to reproduce Figure S1 is available as a vignette in the <bold><italic toggle="yes">kmdata</italic></bold> package.</p>
      </sec>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material id="sup1" position="float" content-type="local-data">
      <label>baab037_Supp</label>
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="baab037_supp.zip">
        <caption>
          <p>Click here for additional data file.</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
</body>
<back>
  <sec id="s5">
    <title>Supplementary data</title>
    <p><xref rid="sup1" ref-type="supplementary-material">Supplementary data</xref> are available at <italic toggle="yes">Database</italic> online.</p>
  </sec>
  <sec id="s6">
    <title>Funding</title>
    <p>Project Data Sphere and the National Institutes of Health (NIH Grant 1R01LM013352-01A1, to S.V. and L.T.).</p>
  </sec>
  <sec id="s7">
    <title>Conflict of interest.</title>
    <p>None declared.</p>
  </sec>
  <ref-list id="ref1">
    <title>References</title>
    <ref id="R1">
      <label>1.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rahman</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fell</surname><given-names>G.</given-names></string-name>, <string-name><surname>Ventz</surname><given-names>S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2019</year>) <article-title>Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications</article-title>. <source><italic toggle="yes">Clin. Cancer Res.</italic></source>, <volume>25</volume>, <fpage>6339</fpage>–<lpage>6345</lpage>.<pub-id pub-id-type="pmid">31345838</pub-id></mixed-citation>
    </ref>
    <ref id="R2">
      <label>2.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rahman</surname><given-names>R.</given-names></string-name>, <string-name><surname>Fell</surname><given-names>G.</given-names></string-name>, <string-name><surname>Ventz</surname><given-names>S.</given-names></string-name></person-group><etal>et al.</etal> (<year>2019</year>) <article-title>Deviation from the proportional hazards assumption in randomized phase 3 clinical trials in oncology: prevalence, associated factors, and implications</article-title>. <source><italic toggle="yes">Clin. Cancer Res.</italic></source>, <volume>25</volume>, <fpage>6339</fpage>–<lpage>6345</lpage>.doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-3999</pub-id>.<pub-id pub-id-type="pmid">31345838</pub-id></mixed-citation>
    </ref>
    <ref id="R3">
      <label>3.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Agarwala</surname><given-names>V.</given-names></string-name>, <string-name><surname>Khozin</surname><given-names>S.</given-names></string-name>, <string-name><surname>Singal</surname><given-names>G.</given-names></string-name></person-group><etal>et al.</etal> (<year>2018</year>) <article-title>Real-world evidence in support of precision medicine: clinico-genomic cancer data as a case study</article-title>. <source><italic toggle="yes">Health Aff.</italic></source>, <volume>37</volume>, <fpage>765</fpage>–<lpage>772</lpage>.</mixed-citation>
    </ref>
    <ref id="R4">
      <label>4.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Corrigan-Curay</surname><given-names>J.</given-names></string-name>, <string-name><surname>Sacks</surname><given-names>L.</given-names></string-name> and <string-name><surname>Woodcock</surname><given-names>J.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Real-world evidence and real-world data for evaluating drug safety and effectiveness</article-title>. <source><italic toggle="yes">JAMA</italic></source>, <volume>320</volume>, <fpage>867</fpage>–<lpage>868</lpage>.<pub-id pub-id-type="pmid">30105359</pub-id></mixed-citation>
    </ref>
    <ref id="R5">
      <label>5.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ventz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Lai</surname><given-names>A.</given-names></string-name>, <string-name><surname>Cloughesy</surname><given-names>T.F.</given-names></string-name></person-group><etal>et al.</etal> (<year>2019</year>) <article-title>Design and evaluation of an external control arm using prior clinical trials and real-world data</article-title>. <source><italic toggle="yes">Clin. Cancer Res.</italic></source>, <volume>25</volume>, <fpage>4993</fpage>–<lpage>5001</lpage>.doi: <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-19-0820</pub-id>.<pub-id pub-id-type="pmid">31175098</pub-id></mixed-citation>
    </ref>
    <ref id="R6">
      <label>6.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ventz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Bacallado</surname><given-names>S.</given-names></string-name>, <string-name><surname>Rahman</surname><given-names>R.</given-names></string-name></person-group><etal>et al.</etal> (<year>2021</year>) <article-title>The effects of releasing early results from ongoing clinical trials</article-title>. <source><italic toggle="yes">Nat. Commun.</italic></source>, <volume>12</volume>, <fpage>1</fpage>–<lpage>7</lpage>.<pub-id pub-id-type="pmid">33397941</pub-id></mixed-citation>
    </ref>
    <ref id="R7">
      <label>7.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Arfè</surname><given-names>A.</given-names></string-name>, <string-name><surname>Alexander</surname><given-names>B.</given-names></string-name> and <string-name><surname>Trippa</surname><given-names>L.</given-names></string-name></person-group> (<year>2020</year>) <article-title>Optimality of testing procedures for survival data in the nonproportional hazards setting</article-title>. <source><italic toggle="yes">Biometrics</italic></source>.doi: <pub-id pub-id-type="doi">10.1111/biom.13315</pub-id>.</mixed-citation>
    </ref>
    <ref id="R8">
      <label>8.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Alexander</surname><given-names>B.M.</given-names></string-name>, <string-name><surname>Schoenfeld</surname><given-names>J.D.</given-names></string-name> and <string-name><surname>Trippa</surname><given-names>L.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Hazards of hazard ratios-deviations from model assumptions in immunotherapy</article-title>. <source><italic toggle="yes">N. Engl. J. Med.</italic></source>, <volume>378</volume>, <fpage>1158</fpage>–<lpage>1159</lpage>.<pub-id pub-id-type="pmid">29562148</pub-id></mixed-citation>
    </ref>
    <ref id="R9">
      <label>9.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uno</surname><given-names>H.</given-names></string-name>, <string-name><surname>Claggett</surname><given-names>B.</given-names></string-name>, <string-name><surname>Tian</surname><given-names>L.</given-names></string-name></person-group><etal>et al.</etal> (<year>2014</year>) <article-title>Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis</article-title>. <source><italic toggle="yes">J. Clin. Oncol.</italic></source>, <volume>32</volume>, <fpage>2380</fpage>–<lpage>2385</lpage>.<pub-id pub-id-type="pmid">24982461</pub-id></mixed-citation>
    </ref>
    <ref id="R10">
      <label>10.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Trippa</surname><given-names>L.</given-names></string-name>, <string-name><surname>Lee</surname><given-names>E.Q.</given-names></string-name>, <string-name><surname>Wen</surname><given-names>P.Y.</given-names></string-name></person-group><etal>et al.</etal> (<year>2012</year>) <article-title>Bayesian adaptive randomized trial design for patients with recurrent glioblastoma</article-title>. <source><italic toggle="yes">J. Clin. Oncol.</italic></source>, <volume>30</volume>, <fpage>3258</fpage>–<lpage>3263</lpage>.<pub-id pub-id-type="pmid">22649140</pub-id></mixed-citation>
    </ref>
    <ref id="R11">
      <label>11.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ventz</surname><given-names>S.</given-names></string-name>, <string-name><surname>Trippa</surname><given-names>L.</given-names></string-name> and <string-name><surname>Schoenfeld</surname><given-names>J.D.</given-names></string-name></person-group> (<year>2019</year>) <article-title>Lessons learned from de-escalation trials in favorable risk HPV-associated squamous cell head and neck cancer - a perspective on future trial designs</article-title>. <source><italic toggle="yes">Clin. Cancer Res.</italic></source>, <volume>25</volume>, <fpage>7281</fpage>–<lpage>7286</lpage>.doi: <pub-id pub-id-type="doi">10.1158/1078-0432.ccr-19-0945</pub-id>.<pub-id pub-id-type="pmid">31527164</pub-id></mixed-citation>
    </ref>
    <ref id="R12">
      <label>12.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rubinstein</surname><given-names>S.M.</given-names></string-name> and <string-name><surname>Warner</surname><given-names>J.L.</given-names></string-name></person-group> (<year>2018</year>) <article-title>CancerLin Q: origins, implementation, and future directions</article-title>. <source><italic toggle="yes">JCO Clin Cancer Inform.</italic></source>, <volume>2</volume>, <fpage>1</fpage>–<lpage>7</lpage>.</mixed-citation>
    </ref>
    <ref id="R13">
      <label>13.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krumholz</surname><given-names>H.M.</given-names></string-name> and <string-name><surname>Waldstreicher</surname><given-names>J.</given-names></string-name></person-group> (<year>2016</year>) <article-title>The Yale Open Data Access (YOD) project — a mechanism for data sharing</article-title>. <source><italic toggle="yes">N. Engl. J. Med.</italic></source>, <volume>375</volume>, <fpage>403</fpage>–<lpage>405</lpage>.<pub-id pub-id-type="pmid">27518657</pub-id></mixed-citation>
    </ref>
    <ref id="R14">
      <label>14.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Miller</surname><given-names>R.S.</given-names></string-name> and <string-name><surname>Wong</surname><given-names>J.L.</given-names></string-name></person-group> (<year>2018</year>) <article-title>Using oncology real-world evidence for quality improvement and discovery: the case for ASCO’s CancerLinQ</article-title>. <source><italic toggle="yes">Future Oncol.</italic></source>, <volume>14</volume>, <fpage>5</fpage>–<lpage>8</lpage>.</mixed-citation>
    </ref>
    <ref id="R15">
      <label>15.</label>
      <mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Collett</surname><given-names>D.</given-names></string-name></person-group> (<year>2015</year>) <source><italic toggle="yes">Modelling Survival Data in Medical Research</italic></source>. <edition>3rd</edition> edn. <publisher-loc>CRC Press, Boca Raton</publisher-loc>, <publisher-name>FL, US</publisher-name>.</mixed-citation>
    </ref>
    <ref id="R16">
      <label>16.</label>
      <mixed-citation publication-type="other"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.digitizeit.de/" ext-link-type="uri">https://www.digitizeit.de/</ext-link>. <source>(software)</source>.</mixed-citation>
    </ref>
    <ref id="R17">
      <label>17.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guyot</surname><given-names>P.</given-names></string-name>, <string-name><surname>Ades</surname><given-names>A.E.</given-names></string-name>, <string-name><surname>Ouwens</surname><given-names>M.J.N.M.</given-names></string-name></person-group><etal>et al.</etal> (<year>2012</year>) <article-title>Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves</article-title>. <source><italic toggle="yes">BMC Med. Res. Methodol.</italic></source>, <volume>12</volume>, <fpage>1</fpage>–<lpage>13</lpage>.doi: <pub-id pub-id-type="doi">10.1186/1471-2288-12-9</pub-id>.<pub-id pub-id-type="pmid">22214542</pub-id></mixed-citation>
    </ref>
    <ref id="R18">
      <label>18.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>R-Core-Team</collab></person-group>. (<year>2018</year>) <article-title>A language and environment for statistical computing</article-title>. <source><italic toggle="yes">R Found Stat. Comput.</italic></source>, <volume>2</volume>, <fpage>1</fpage>–<lpage>201</lpage>. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.r-project.org" ext-link-type="uri">http://www.r-project.org</ext-link> (11 January 2020, date last accessed).</mixed-citation>
    </ref>
    <ref id="R19">
      <label>19.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoshioka</surname><given-names>H.</given-names></string-name>, <string-name><surname>Azuma</surname><given-names>K.</given-names></string-name>, <string-name><surname>Yamamoto</surname><given-names>N.</given-names></string-name></person-group><etal>et al.</etal> (<year>2015</year>) <article-title>A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal</article-title>. <source><italic toggle="yes">Ann. Oncol.</italic></source>, <volume>26</volume>, <fpage>2066</fpage>–<lpage>2072</lpage>.<pub-id pub-id-type="pmid">26153496</pub-id></mixed-citation>
    </ref>
    <ref id="R20">
      <label>20.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Green</surname><given-names>A.K.</given-names></string-name>, <string-name><surname>Reeder‐Hayes</surname><given-names>K.E.</given-names></string-name>, <string-name><surname>Corty</surname><given-names>R.W.</given-names></string-name></person-group><etal>et al.</etal> (<year>2015</year>) <article-title>The project data sphere initiative: accelerating cancer research by sharing data</article-title>. <source><italic toggle="yes">Oncologist</italic></source>, <volume>20</volume>, <fpage>464</fpage>–<lpage>e20</lpage>.<pub-id pub-id-type="pmid">25876994</pub-id></mixed-citation>
    </ref>
    <ref id="R21">
      <label>21.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mackey</surname><given-names>J.R.</given-names></string-name>, <string-name><surname>Ramos-Vazquez</surname><given-names>M.</given-names></string-name>, <string-name><surname>Lipatov</surname><given-names>O.</given-names></string-name></person-group><etal>et al.</etal> (<year>2015</year>) <article-title>Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer</article-title>. <source><italic toggle="yes">J. Clin. Oncol.</italic></source>, <volume>33</volume>, <fpage>141</fpage>–<lpage>148</lpage>.<pub-id pub-id-type="pmid">25185099</pub-id></mixed-citation>
    </ref>
    <ref id="R22">
      <label>22.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thatcher</surname><given-names>N.</given-names></string-name>, <string-name><surname>Hirsch</surname><given-names>F.R.</given-names></string-name>, <string-name><surname>Luft</surname><given-names>A.V.</given-names></string-name></person-group><etal>et al.</etal> (<year>2015</year>) <article-title>Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial</article-title>. <source><italic toggle="yes">Lancet Oncol.</italic></source>, <volume>16</volume>, <fpage>763</fpage>–<lpage>774</lpage>.<pub-id pub-id-type="pmid">26045340</pub-id></mixed-citation>
    </ref>
    <ref id="R23">
      <label>23.</label>
      <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ihaka</surname><given-names>R.</given-names></string-name> and <string-name><surname>Gentleman</surname><given-names>R.R.</given-names></string-name></person-group> (<year>1996</year>) <article-title>A language for data analysis and graphics</article-title>. <source><italic toggle="yes">J. Comput. Graph Stat.</italic></source>, <volume>5</volume>, <fpage>299</fpage>–<lpage>314</lpage>.</mixed-citation>
    </ref>
  </ref-list>
</back>
